利生奇珠单抗南京首张医保处方落地！中重度克罗恩病患者迎来福音

Core Insights - The implementation of the new national medical insurance drug list in 2025 has enabled the first medical insurance prescription for Risankizumab in Nanjing, significantly reducing the economic burden on Crohn's disease patients and improving their quality of life [1][3]. Group 1: Disease Overview - Crohn's disease, a major subtype of inflammatory bowel disease (IBD), is characterized by chronic recurrent inflammation of the digestive tract and is often referred to as "green cancer" due to its severe impact on patients' quality of life [3]. - The incidence of IBD in East Asia is accelerating, with the number of patients in China increasing at a rate of 5% to 10% annually [3]. Group 2: Treatment Advancements - Risankizumab has demonstrated significant therapeutic advantages in clinical studies and has been approved in over 40 countries, benefiting more than 40,000 patients with proven safety and efficacy [3]. - As the first interleukin-23 inhibitor approved for treating moderate to severe active Crohn's disease, Risankizumab offers a more precise treatment option for patients [3]. Group 3: Clinical Center Development - The Gastroenterology Department at Taikang Xianlin Gu Lou Hospital is recognized as a provincial clinical key specialty and has made significant advancements under the leadership of renowned expert Professor Zou Xiaoping [5]. - The newly established Small Intestine and Inflammatory Bowel Disease Diagnosis and Treatment Center focuses on key aspects of IBD management, integrating diagnostic and therapeutic approaches for comprehensive patient care [6].